Opendata, web and dolomites

OvaVAx SIGNED

100% Bacteria free eggs for use in production of human and animal vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OvaVAx project word cloud

Explore the words cloud of the OvaVAx project. It provides you a very rough idea of what is the project "OvaVAx" about.

coo    catherine    pull    protect    expertise    91m    ovagen    cagr    good    ltd    pandemic    agr    12    spf    commercially       vaccine    seven    biopharma    germ    2021    worth    89bn    skills    specialist    company    manufacture    pharmaceutical    opportunity    enterprise    globally    1bn    team    health    ogl    services    pathogen    led    vc    lives    immunisation    contract    demand    standards    exceptionally    avian    populations    yields    usd    manufacturing    first    eggs    biotechnology    world    egg    industry    yield    considerable    whilst    viral    utilising    serial    transgenics    rapid    caulfield       invested    servicing    specialises    48bn    contamination    market    providers    patent    2022    vision    leonard    benefits    chicken    founders    fertilised    disruptive    manufacturers    free    global    annually    ceo    dr    entrepreneurs    service    demands    investors    supplier    gf    quality    ireland    external    vaccines    superior    moran    size    group    industries    protected    innovation    eliminate    innovative    bacterial   

Project "OvaVAx" data sheet

The following table provides information about the project.

Coordinator
OVAGEN GROUP LIMITED 

Organization address
address: CARRENTRILA
city: BALLINA
postcode: F26PC79
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙366˙875 €
 EC max contribution 2˙356˙812 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OVAGEN GROUP LIMITED IE (BALLINA) coordinator 2˙356˙812.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Disruptive technology for improved quality and viral yield in egg-based vaccine production and other biotechnology applications. Ovagen Group Ltd. (OGL) is an innovation-based biotechnology company, led by serial entrepreneurs, providing specialist contract services to Biopharma, Pharmaceutical and Vaccine industries. OGL specialises in avian Germ-Free (GF) technology and avian transgenics to Good Manufacturing Practice standards. The company’s vision is to be the go-to supplier of superior quality GF eggs to the vaccine industry globally by 2021.

INNOVATION: The founders Dr Leonard Moran CEO and Dr Catherine Caulfield COO together with external VC investors and Enterprise Ireland have invested €12.91M in seven years of R&D, utilising the considerable skills, expertise and experience of our team within this field to develop a unique and novel, patent protected process to enable commercially viable production of the World’s first germ-free (GF) eggs, to eliminate bacterial contamination through eggs for vaccine development and production. This will result in improved quality, production costs and viral yields for vaccine manufacturers leading to cost and availability benefits for health service providers for immunisation programmes to protect the health and lives of populations whilst enabling a rapid response to Global pandemic demands. There is exceptionally strong market pull for our innovative disruptive technology, and the increasing use of vaccines to support global demand for quality eggs estimated CAGR of 8.8% and market value of USD 1.89Bn by 2022.

OPPORTUNITY: Over 1bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, servicing a vaccine market size estimated to be worth €48bn by 2021 with an AGR of 8.3%.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

SiC-MOSFET (2019)

Gas Sensors for future Ultra Low NOx Emission Legislation – Euro 7

Read More  

MHS (2019)

Metal Hydrides Hydrogen Storage

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More